

Supplement B

Supplementary Table 1. Minimal Inhibitory Concentrations (MIC) for individual patients in the placebo and azithromycin groups. MIC values were evaluated in triplicates and are given in mg/L.

	Placebo (n = 5)	Azithromycin (n = 4)
Visit	Median MIC in mg/L	Median MIC in mg/L
Baseline	0.5	0.5
Visit 1	0.5	0.5
Visit 2	0.5	0.5
Baseline	32	32
Visit 1	32	32
Visit 2	32	32
Baseline	1	32
Visit 1	1	32
Visit 2	1	32
Baseline	1	32
Visit 1	1	32
Visit 2	1	32
Baseline	1	
Visit 1	1	
Visit 2	1	

Supplementary Table 2. Median/range of inflammatory markers in the azithromycin and placebo groups at each of the three visits.

Characteristics	Azithromycin						Placebo					
	Visit 1 Median (Range)		Visit 2 Median (Range)		End of study Median (Range)		Visit 1 Median (Range)		Visit 2 Median (Range)		End of study Median (Range)	
<i>NLR</i>	2.95	0.08; 12.91	2.55	0.63; 20.68	3.05	1.00; 18.57	4.38	1.35; 25.00	3.03	0.82; 20.40	2.33	1; 15.25
<i>LLR</i>	4.71	1.2; 14.34	4.26	1.89; 25.16	4.84	0.03; 33.21	5.86	2.86; 27.57	4.77	2.23; 22.36	4.06	0.03; 18.73
<i>PLR</i>	176.9	7.3; 597.1	206.5	39.8; 787.8	159.3	1.7; 875.6	283.6	71.4; 1586.7	211.7	90.2; 1138.8	149.9	1.18; 566.7
<i>MLR</i>	0.40	0.02; 5.62	0.50	0.13; 1.53	0.43	0.13; 6.53	0.43	0.00; 4.61	0.51	0.04; 1.81	0.41	0.17; 2.69
<i>CRP</i>	0.35	0.03; 5.78	0.36	0.02; 9.67	0.46	0.05; 17.29	0.54	0.03; 10.14	0.41	0.03; 20.30	0.34	0.03; 3.17
<i>CRP/Alb</i>	0.90	0.07; 15.64	0.96	0.07; 26.79	1.24	0.12; 75.5	1.32	0.07; 29.31	1.16	0.07; 63.24	0.86	0.08; 9.03
<i>PCT</i>	0.05	0.02; 13.99	0.05	0.02; 99.00	0.06	0.02; 1.65	0.04	0.02; 14.00	0.04	0.02; 99.00	0.04	0.02; 15.8
<i>IL-6</i>	4.19	1.50; 48.42	5.92	1.50; 60.57	4.38	1.50; 32.85	2.95	0.33; 99.00	4.24	1.5; 31.10	4.17	1.5; 21.77

CRP: C-reactive protein, NLR: neutrophil/lymphocyte ratio, LLR: leukocyte/lymphocyte ratio, PLR: platelet/lymphocyte ratio, MLR: monocyte/lymphocyte ratio, CRP/Alb: C-reactive protein/albumin ratio, IL-6: Interleukin-6, PCT: Procalcitonin

Supplementary Table 3. Generalized linear mixed model predicting the neutrophil/lymphocyte ratio (NLR). Likelihood ratio test (LRT) for interaction between treatment group and visit: $p = 0.008$.

Parameter	Coefficient	SE	p-value
<i>Intercept</i>	1.66	0.163	
<i>Verum</i>	-0.60	0.230	0.009
<i>Follow-up 1</i>	-0.51	0.165	0.002
<i>Follow-up 2</i>	-0.64	0.175	<0.001
<i>Verum x Follow-up 1</i>	0.41	0.232	0.077
<i>Verum x Follow-up 2</i>	0.76	0.244	0.002

Supplementary Table 4. Generalized linear mixed model predicting the leukocyte/lymphocyte ratio (LLR). Likelihood ratio test (LRT) for interaction between treatment group and visit: $p = 0.004$.

Parameter	Coefficient	SE	p-value
<i>Intercept</i>	2.02	0.109	
<i>Verum</i>	-0.43	0.154	0.005
<i>Follow-up 1</i>	-0.36	0.102	<0.001
<i>Follow-up 2</i>	-0.47	0.123	<0.001
<i>Verum x Follow-up 1</i>	0.33	0.144	0.024
<i>Verum x Follow-up 2</i>	0.57	0.171	0.001

Supplementary Table 5. Generalized linear mixed model predicting the platelet/lymphocyte ratio (PLR). Likelihood ratio test (LRT) for interaction between treatment group and visit: $p = 0.116$.

Parameter	Coefficient	SE	p-value
<i>Intercept</i>	5.54	0.117	
<i>Verum</i>	-0.23	0.132	0.082
<i>Follow-up 1</i>	-0.11	0.089	0.222
<i>Follow-up 2</i>	-0.26	0.114	0.020

Supplementary Table 6. Generalized linear mixed model predicting the monocyte/lymphocyte ratio (MLR). Likelihood ratio test (LRT) for interaction between treatment group and visit: $p = 0.621$.

Parameter	Coefficient	SE	p-value
<i>Intercept</i>	-0.61	0.109	
<i>Verum</i>	0.01	0.119	0.946
<i>Follow-up 1</i>	0.03	0.097	0.735
<i>Follow-up 2</i>	0.10	0.099	0.333

Supplementary Table 7. Generalized linear mixed model predicting C-reactive protein (CRP) levels. Likelihood ratio test (LRT) for interaction between treatment group and visit: $p = 0.173$.

Parameter	Coefficient	SE	p-value
<i>Intercept</i>	-0.35	0.206	
<i>Verum</i>	-0.02	0.268	0.933
<i>Follow-up 1</i>	-0.07	0.105	0.523
<i>Follow-up 2</i>	-0.07	0.143	0.642

Supplementary Table 8. Generalized linear mixed model predicting the CRP/albumin ratio (CRP/alb). Likelihood ratio test (LRT) for interaction between treatment group and visit: $p = 0.097$.

Parameter	Coefficient	SE	p-value
<i>Intercept</i>	0.23	0.274	
<i>Verum</i>	-0.04	0.356	0.904
<i>Follow-up 1</i>	0.01	0.155	0.926
<i>Follow-up 2</i>	-0.01	0.188	0.954

Supplementary Table 9. Generalized linear mixed model predicting procalcitonin (PCT) levels. Likelihood ratio test (LRT) for interaction between treatment group and visit: p = 0.234.

Parameter	Coefficient	SE	p-value
<i>Intercept</i>	-1.51	0.162	
<i>Verum</i>	-0.16	0.193	0.411
<i>Follow-up 1</i>	-0.08	0.093	0.409
<i>Follow-up 2</i>	-0.03	0.095	0.770

Supplementary Table 10. Generalized linear mixed model predicting interleukin-6 (IL-6) levels. Likelihood ratio test (LRT) for interaction between treatment group and visit: p = 0.729.

Parameter	Coefficient	SE	p-value
<i>Intercept</i>	1.34	0.174	
<i>Verum</i>	0.19	0.222	0.387
<i>Follow-up 1</i>	0.20	0.104	0.053
<i>Follow-up 2</i>	0.18	0.124	0.148